Removing the senescent cells from the plaque is conceptually a good idea, but given the multiple detrimental effects of ABT-263 in our WD-fed Apoe–/– mice, further preclinical studies with senolytic drugs are needed to identify factors and mechanisms that modulate senolytic drugs biological effects before planning a large clinical trial targeting atherosclerosis. The gene discussed is APOE; the disease is atherosclerosis.